RSV 604
Alternative Names: A-60444; RSV-604Latest Information Update: 22 Jul 2015
At a glance
- Originator Arrow Therapeutics
- Developer Arrow Therapeutics; Novartis
- Class Antivirals; Benzodiazepinones; Phenylurea compounds; Small molecules
- Mechanism of Action Nucleocapsid protein inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 16 Nov 2010 RSV 604 is still in active development
- 02 Oct 2008 Preclinical trials in Respiratory syncytial virus infections (in infants) in United Kingdom (PO)
- 31 Oct 2006 Phase-I clinical trials in Respiratory syncytial virus infections in volunteers United Kingdom (IV)